BNET Industries
- Public
Dow Jones Description
In January 2006 the company was acquired by Teva Pharmaceutical Industries Ltd of Jerusalem, Israel.
President
Neil W. FlanzraichContact Information
Peer Companies
NAICS Code : 541710
Recent Events
-
Heavy hitters invest $31M in Opko
News & Analysis
Filter by
ivax corp. and tablet - All News and Analysis
IVAX Receives Final Approval on Clozapine Tablet
MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) announced today that it has received final approval from the U.S. Food and Drug Administration FDA for its Abbreviated New Drug Application ANDA for clozapine tablets USP, 200 mg. This product will be sold through IVAX' wholly owned subsidiary, IVAX Pharmaceuticals, Inc. Clozapine...
IVAX to Begin Sale of Morphine Sulfate Controlled-Release Tablets C-II as Authorized Distributor
MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) announced today that its U.S. generic subsidiary, IVAX Pharmaceuticals, Inc., will distribute, in the United States, morphine sulfate controlled-release tablets C-II in 15, 30, 60, 100 and 200 mg dosage strengths supplied by Purdue Pharma LP of Stamford, Connecticut. Morphine sulfate controlled-release tablets...
IVAX Receives Final Approval for Doxycycline Hyclate Tablets
MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) has received final approval from the U.S. Food and Drug Administration FDA for its Abbreviated New Drug Application ANDA for doxycycline hyclate 20 mg tablets. This product will be sold through IVAX' wholly owned subsidiary, IVAX Pharmaceuticals, Inc. Doxycycline hyclate 20 mg tablets...
IVAX Receives Final Approval on 600 and 800 mg Gabapentin Tablets
MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) announced today that it received final approval on April 29, 2005 from the U.S. Food and Drug Administration FDA for its Abbreviated New Drug Application ANDA for gabapentin 600 and 800 mg tablets. Upon FDA approval, IVAX' wholly owned subsidiary, IVAX Pharmaceuticals, Inc.,...
IVAX to Begin Marketing Gabapentin Capsules in March, Tablets in April, Prior to End of Alpharma's Exclusivity Periods
MIAMI -- IVAX Corporation Announces Settlement of Litigation Against FDA and Alpharma
IVAX Receives Final Approval of Tizanidine HCL Tablets
MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) announced today that it has received final approval from the Federal Food and Drug Administration FDA for its Abbreviated New Drug Application ANDA for tizanidine HCl in 2 mg and 4 mg tablet dosages. These tablets will be sold through the company's wholly owned...
IVAX Launches Gabapentin Tablets
MIAMI -- IVAX Corporation (AMEX:IVX)(LSE:IVX.L) announced today that it has commenced the initial commercialization of its gabapentin tablets in 100 mg, 300 mg and 400 mg strengths to selected customers. IVAX received final approval of its Abbreviated New Drug Application for these tablets from the FDA in April 2004. As...
Ivax Gets Drug OK
IVAX CORPORATION, Miami, Fla., has been granted final marketing approval for etodolac and acyclovir by US Food & Drug Administration. Ivax says it has already begun offering 400 mg tablets of etodolac, the generic equivalent of ... IVAX CORPORATION, Miami, Fla., has...
Ivax Ready to Market Generic Terfenadine
IVAX CORPORATION has received final marketing approval for the allergy medication terfenadine in 60 mg tablets from Food & Drug Administration. The company says it is the first to receive approval for terfenadine, which is the generic equival IVAX CORPORATION has received...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Neil W. Flanzraich | President |
| Jimmy Wang | CIO & Vice President |
| Nicholas Bodor | Chief Scientific Officer |
| Thomas E. Beier | CFO & Senior Vice President, Finance |
| Thomas E. McClary | Chief Accounting Officer |
| Rafick Henein | Senior Vice President |
| Steven D. Rubin | General Counsel, Senior Vice President & Secretary |
| Edmund Fry | Vice President, Compliance |
| J. Michael Lopez | Vice President, HR |
| Michael M. Lopez | Vice President, HR |
| Rao Uppaluri | Vice President, Strategic Planning |
| Roberto Prego | Vice President, Latin America |
| Stephen Sheriff | Vice President, Taxation & Tax Counsel |
| David Malina | Director, Investor Relations & Corp Communications |
| Hans Berner Soto | Director, Operations, Latin America |
| Organization | Position | Status |
|---|---|---|
| IVAX Corporation | President | Current |
| Equity One, Inc. | Vice Chairman and President | Current |
| BELLUS Health Inc. | Consultant | Current |
| RAE Systems Inc. | Member, Chair | Current |
| Equity One, Inc. | Board of Directors | Current |
| Continucare Corporation | Director | Current |
| Chipotle Mexican Grill, Inc. | Director | Current |
| BELLUS Health Inc. | Director | Current |
| IVAX Corporation | Vice Chairman | Current |
| Harvard College | A.B | Former |
| Heller Ehrman LLP | Life Sciences Legal Practice Group Team | Former |
| Syntex Corporation | Former | |
| Israelamericafoundation.Com | Chairman | Former |
| RAE Systems Inc. | Board of Directors | Former |
| Harvard Law School | J.D. | Former |
| Harvard College | A.B. | Former |
| Organization | Position | Status |
|---|---|---|
| IVAX Corporation | CIO & Vice President | Current |
| Organization | Position | Status |
|---|---|---|
| IVAX Corporation | Chief Scientific Officer | Current |
| Organization | Position | Status |
|---|---|---|
| IVAX Corporation | CFO & Senior Vice President, Finance | Current |
| IVAX Diagnostics, Inc. | Cfo | Former |
| Organization | Position | Status |
|---|---|---|
| IVAX Corporation | Chief Accounting Officer | Current |
| IVAX Diagnostics, Inc. | Vice President, Finance | Current |
| Organization | Position | Status |
|---|---|---|
| IVAX Corporation | Senior Vice President | Current |
| Bioxelpharma Inc. | Board of Directors | Current |
| Ontario College of Pharmacists | Board of Directors | Current |
| Geopharma, Inc. | Director | Current |
| Dex-C20 | Director | Current |
| Ontario College of Pharmacists | Member | Current |
| IVAX Pharmaceuticals Inc. | President & CEO | Former |
| Novopharm Limited | Chief Operating Officer | Former |
| Novopharm Limited | Executive Vice President | Former |
| McGill University | Diploma In Management | Former |
| McGill University | MBA | Former |
| McGill University | Diploma In Management | Former |
| Organization | Position | Status |
|---|---|---|
| IVAX Corporation | General Counsel, Senior Vice President & Secretary | Current |
| Organization | Position | Status |
|---|---|---|
| IVAX Corporation | Vice President, Compliance | Current |
| Organization | Position | Status |
|---|---|---|
| IVAX Corporation | Vice President, HR | Current |
| Organization | Position | Status |
|---|---|---|
| IVAX Diagnostics, Inc. | Vice President, HR | Current |
| IVAX Corporation | Vice President, HR | Current |
| Organization | Position | Status |
|---|---|---|
| IVAX Corporation | Vice President, Strategic Planning | Current |
| IVAX Diagnostics, Inc. | Vice President, Strategic Planning | Current |
| Organization | Position | Status |
|---|---|---|
| IVAX Corporation | Vice President, Latin America | Current |
| IVAX Diagnostics, Inc. | Vice President | Current |
| Organization | Position | Status |
|---|---|---|
| IVAX Diagnostics, Inc. | Vice President | Current |
| IVAX Corporation | Vice President, Taxation & Tax Counsel | Current |
| Organization | Position | Status |
|---|---|---|
| IVAX Corporation | Director, Investor Relations & Corp Communications | Current |
| IVAX Corporation | Director, Investor Relations & Corp Communications | Former |
| Organization | Position | Status |
|---|---|---|
| IVAX Corporation | Director, Operations, Latin America | Current |



